B-intervention	0	8	Eribulin
I-intervention	9	20	monotherapy
O	21	23	in
O	24	32	patients
O	33	37	aged
B-age	38	40	70
I-age	41	46	years
I-age	47	50	and
I-age	51	56	older
O	57	61	with
O	62	72	metastatic
O	73	79	breast
O	80	86	cancer
O	86	87	.

O	88	97	Following
O	98	101	the
O	102	114	demonstrated
O	115	123	efficacy
O	124	127	and
O	128	134	safety
O	135	137	of
O	138	146	eribulin
O	147	155	mesylate
O	156	158	in
O	159	166	heavily
O	167	177	pretreated
O	178	186	patients
O	187	191	with
O	192	202	metastatic
O	203	209	breast
O	210	216	cancer
O	216	217	,
O	218	220	an
O	221	232	exploratory
O	233	241	analysis
O	242	245	was
O	246	255	performed
O	256	258	to
O	259	270	investigate
O	271	274	the
O	275	281	effect
O	282	284	of
O	285	288	age
O	289	291	in
O	292	297	these
O	298	306	patients
O	306	307	.

O	308	312	Data
O	313	317	were
O	318	324	pooled
O	325	329	from
O	330	333	two
O	334	340	single
O	340	341	-
O	341	344	arm
O	345	350	phase
O	351	353	II
O	354	361	studies
O	362	365	and
O	366	369	one
O	370	374	open
O	374	375	-
O	375	380	label
O	381	391	randomized
O	392	397	phase
O	398	401	III
O	402	407	study
O	408	410	in
O	411	416	which
O	417	425	patients
O	426	434	received
O	435	443	eribulin
O	444	452	mesylate
O	453	455	at
O	456	457	1
O	457	458	.
O	458	459	4
O	460	462	mg
O	462	463	/
O	463	464	m
O	464	465	(
O	465	466	2
O	466	467	)
O	468	470	as
O	471	472	2
O	472	473	-
O	474	476	to
O	477	478	5
O	478	479	-
O	479	485	minute
O	486	497	intravenous
O	498	507	infusions
O	508	510	on
O	511	515	days
O	516	517	1
O	518	521	and
O	522	523	8
O	524	526	of
O	527	528	a
O	529	531	21
O	531	532	-
O	532	535	day
O	536	541	cycle
O	541	542	.

O	543	546	The
O	547	553	effect
O	554	556	of
O	557	560	age
O	561	563	on
O	564	570	median
O	571	578	overall
O	579	587	survival
O	588	589	(
O	589	591	OS
O	591	592	)
O	592	593	,
O	594	605	progression
O	605	606	-
O	606	610	free
O	611	619	survival
O	620	621	(
O	621	624	PFS
O	624	625	)
O	625	626	,
O	627	634	overall
O	635	643	response
O	644	648	rate
O	649	650	(
O	650	653	ORR
O	653	654	)
O	654	655	,
O	656	664	clinical
O	665	672	benefit
O	673	677	rate
O	678	679	(
O	679	682	CBR
O	682	683	)
O	683	684	,
O	685	688	and
O	689	698	incidence
O	699	701	of
O	702	709	adverse
O	710	716	events
O	717	718	(
O	718	721	AEs
O	721	722	)
O	723	726	was
O	727	737	calculated
O	738	741	for
O	742	746	four
O	747	750	age
O	751	757	groups
O	758	759	(
O	759	760	<
O	760	762	50
O	763	768	years
O	768	769	,
O	770	772	50
O	772	773	-
O	773	775	59
O	776	781	years
O	781	782	,
O	783	785	60
O	785	786	-
O	786	788	69
O	789	794	years
O	794	795	,
O	796	797	≥
O	798	800	70
O	801	806	years
O	806	807	)
O	807	808	.

O	809	816	RESULTS
O	816	817	.

O	818	825	Overall
O	825	826	,
B-total-participants	827	830	827
O	831	839	patients
O	840	844	were
O	845	853	included
O	854	856	in
O	857	860	the
O	861	869	analysis
O	870	871	(
O	871	872	<
O	872	874	50
O	875	880	years
O	880	881	,
O	882	883	n
O	884	885	=
B-control-participants	886	889	253
O	889	890	;
O	891	893	50
O	893	894	-
O	894	896	59
O	897	902	years
O	902	903	,
O	904	905	n
O	906	907	=
B-control-participants	908	911	289
O	911	912	;
O	913	915	60
O	915	916	-
O	916	918	69
O	919	924	years
O	924	925	,
O	926	927	n
O	928	929	=
B-control-participants	930	933	206
O	933	934	;
O	935	936	≥
O	937	939	70
O	940	945	years
O	945	946	,
O	947	948	n
O	949	950	=
B-intervention-participants	951	953	79
O	953	954	)
O	954	955	.

O	956	959	Age
O	960	963	had
O	964	966	no
O	967	978	significant
O	979	985	impact
O	986	988	on
B-outcome	989	991	OS
O	992	993	(
B-cv-cont-median	993	995	11
I-cv-cont-median	995	996	.
I-cv-cont-median	996	997	8
I-cv-cont-median	998	1004	months
O	1004	1005	,
B-cv-cont-median	1006	1008	12
I-cv-cont-median	1008	1009	.
I-cv-cont-median	1009	1010	3
I-cv-cont-median	1011	1017	months
O	1017	1018	,
B-cv-cont-median	1019	1021	11
I-cv-cont-median	1021	1022	.
I-cv-cont-median	1022	1023	7
I-cv-cont-median	1024	1030	months
O	1030	1031	,
O	1032	1035	and
B-iv-cont-median	1036	1038	12
I-iv-cont-median	1038	1039	.
I-iv-cont-median	1039	1040	5
I-iv-cont-median	1041	1047	months
O	1047	1048	,
O	1049	1061	respectively
O	1061	1062	;
O	1063	1064	p
O	1065	1066	=
O	1067	1068	.
O	1068	1070	82
O	1070	1071	)
O	1071	1072	,
B-outcome	1073	1076	PFS
O	1077	1078	(
B-cv-cont-median	1078	1079	3
I-cv-cont-median	1079	1080	.
I-cv-cont-median	1080	1081	5
I-cv-cont-median	1082	1088	months
O	1088	1089	,
B-cv-cont-median	1090	1091	2
I-cv-cont-median	1091	1092	.
I-cv-cont-median	1092	1093	9
I-cv-cont-median	1094	1100	months
O	1100	1101	,
B-cv-cont-median	1102	1103	3
I-cv-cont-median	1103	1104	.
I-cv-cont-median	1104	1105	8
I-cv-cont-median	1106	1112	months
O	1112	1113	,
O	1114	1117	and
B-iv-cont-median	1118	1119	4
I-iv-cont-median	1119	1120	.
I-iv-cont-median	1120	1121	0
I-iv-cont-median	1122	1128	months
O	1128	1129	,
O	1130	1142	respectively
O	1142	1143	;
O	1144	1145	p
O	1146	1147	=
O	1148	1149	.
O	1149	1151	42
O	1151	1152	)
O	1152	1153	,
B-outcome	1154	1157	ORR
O	1158	1159	(
B-cv-cont-median	1159	1161	12
I-cv-cont-median	1161	1162	.
I-cv-cont-median	1162	1163	7
I-cv-cont-median	1163	1164	%
O	1164	1165	,
B-cv-cont-median	1166	1168	12
I-cv-cont-median	1168	1169	.
I-cv-cont-median	1169	1170	5
I-cv-cont-median	1170	1171	%
O	1171	1172	,
B-cv-cont-median	1173	1174	6
I-cv-cont-median	1174	1175	.
I-cv-cont-median	1175	1176	3
I-cv-cont-median	1176	1177	%
O	1177	1178	,
O	1179	1182	and
B-iv-bin-percent	1183	1185	10
I-iv-bin-percent	1185	1186	.
I-iv-bin-percent	1186	1187	1
I-iv-bin-percent	1187	1188	%
O	1188	1189	,
O	1190	1202	respectively
O	1202	1203	)
O	1203	1204	,
O	1205	1207	or
B-outcome	1208	1211	CBR
O	1212	1213	(
B-cv-cont-median	1213	1215	20
I-cv-cont-median	1215	1216	.
I-cv-cont-median	1216	1217	2
I-cv-cont-median	1217	1218	%
O	1218	1219	,
B-cv-cont-median	1220	1222	20
I-cv-cont-median	1222	1223	.
I-cv-cont-median	1223	1224	8
I-cv-cont-median	1224	1225	%
O	1225	1226	,
B-cv-cont-median	1227	1229	20
I-cv-cont-median	1229	1230	.
I-cv-cont-median	1230	1231	4
I-cv-cont-median	1231	1232	%
O	1232	1233	,
O	1234	1237	and
B-iv-bin-percent	1238	1240	21
I-iv-bin-percent	1240	1241	.
I-iv-bin-percent	1241	1242	5
I-iv-bin-percent	1242	1243	%
O	1243	1244	,
O	1245	1257	respectively
O	1257	1258	)
O	1258	1259	.

O	1260	1268	Although
O	1269	1273	some
O	1274	1277	AEs
O	1278	1281	had
O	1282	1288	higher
O	1289	1298	incidence
O	1299	1301	in
O	1302	1308	either
O	1309	1312	the
O	1313	1321	youngest
O	1322	1324	or
O	1325	1328	the
O	1329	1335	oldest
O	1336	1344	subgroup
O	1344	1345	,
O	1346	1351	there
O	1352	1355	was
O	1356	1358	no
O	1359	1366	overall
O	1367	1373	effect
O	1374	1376	of
O	1377	1380	age
O	1381	1383	on
O	1384	1387	the
B-outcome	1388	1397	incidence
I-outcome	1398	1400	of
I-outcome	1401	1404	AEs
O	1405	1406	(
O	1406	1415	including
O	1416	1426	neuropathy
O	1426	1427	,
O	1428	1439	neutropenia
O	1439	1440	,
O	1441	1444	and
O	1445	1455	leukopenia
O	1455	1456	)
O	1456	1457	.

O	1458	1466	Eribulin
O	1467	1478	monotherapy
O	1479	1481	in
O	1482	1487	these
O	1488	1496	selected
O	1497	1502	older
O	1503	1511	patients
O	1512	1516	with
O	1517	1521	good
O	1522	1530	baseline
O	1531	1542	performance
O	1543	1549	status
O	1550	1553	led
O	1554	1556	to
O	1557	1559	OS
O	1559	1560	,
O	1561	1564	PFS
O	1564	1565	,
O	1566	1569	ORR
O	1569	1570	,
O	1571	1574	CBR
O	1574	1575	,
O	1576	1579	and
O	1580	1592	tolerability
O	1593	1600	similar
O	1601	1603	to
O	1604	1609	those
O	1610	1612	of
O	1613	1620	younger
O	1621	1629	patients
O	1630	1634	with
O	1635	1645	metastatic
O	1646	1652	breast
O	1653	1659	cancer
O	1659	1660	.

O	1661	1664	The
O	1665	1673	benefits
O	1674	1677	and
O	1678	1683	risks
O	1684	1686	of
O	1687	1695	eribulin
O	1696	1702	appear
O	1703	1705	to
O	1706	1708	be
O	1709	1716	similar
O	1717	1723	across
O	1724	1727	age
O	1728	1734	groups
O	1734	1735	.
